CTOs on the Move

Selvita

www.selvita.com

 
Selvita is a preclinical Contract Research Organization providing multidisciplinary support in resolving the unique challenges of research within area of drug discovery, regulatory studies, as well as research and development. Selvita is also a major shareholder in Ardigen – a bioinformatics company harnessing advanced Artificial Intelligence methods for novel precision medicine. In January 2021, Selvita acquired 100% of shares in Fidelta d.o.o., substantially expanding its scope of drug discovery services in infectious diseases, inflammation, and fibrosis and building a competitive advantage in areas such as DMPK, in vivo pharmacology, and toxicology. Selvita was established in 2007 and currently employs almost ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $250-500 Million
  • www.selvita.com
  • 611 Gateway Boulevard Suite 120
    South San Francisco, CA USA 94080
  • Phone: 650.660.7899

Executives

Name Title Contact Details

Similar Companies

Alvotech

Alvotech is a fully integrated specialty biopharmaceutical company focused on development and manufacturing of high quality biosimilar medicines.

Alliance Analytical

Alliance Analytical is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Diosynth Biotechnology

Diosynth Biotechnology is a Morrisville, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Whole Biome

Whole Biome`s mission is to be the trusted brand in bringing the public improved health solutions through microbiome interventions. We are developing microbiome diagnostics and interventions using our proprietary discovery platform.

RAPT Therapeutics

RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the company develops highly selective small molecules that are designed to modulate the fundamental immune responses underlying these diseases. RAPT has rapidly discovered and advanced two unique drug candidates each targeting CCR4, including our lead oncology drug candidate, FLX475, now in clinical development and our lead inflammation drug candidate, RPT193, expected to enter the clinic in the second half of 2019. The company is also pursuing other discovery targets including GCN2 and HPK1 for the treatment of cancer.